---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034442"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T22:08:07.392705+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCardia reports Q3 2025 results, $6M financing, and regulatory milestones for cell therapies

## Summary
- Closed $6.0 million financing with net proceeds of $5.2 million in September 2025.
- Net loss decreased to $1.5 million for Q3 2025 from $1.7 million in Q3 2024.
- Positive preliminary clinical consultation with Japan’s PMDA for CardiAMP heart failure trial.
- Plans to submit Helix transendocardial delivery catheter for FDA DeNovo 510(k) in Q4 2025.
- Cash balance of $5.3 million on Sept 30, 2025, providing runway into Q2 2026.

## SEC filing metadata
- accession: 0001437749-25-034442
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/0001437749-25-034442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925034442/bcda20251112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034442
- JSON: https://secwatch.observer/filing/0001437749-25-034442.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034442.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.